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ABSTRACT
Background Parental history of type 2 diabetes (T2D) is associated with cardiometabolic risk. We aimed to
investigate the associations of parental history of T2D with cardiometabolic biomarkers and to subsequently
investigate to what extent these putative associations were explained by modifiable factors.
Materials and methods Cross-sectionally, we analysed a random sample of 2001 participants without T2D
(20–70 years) from the European Prospective Investigation into Cancer and Nutrition–Netherlands (EPIC-NL).
Plasma levels of 12 biomarkers – total, HDL and LDL-cholesterol, triglycerides, HbA1c, gamma-glutamyltransfer-
ase (GGT), alanine aminotransferase (ALT), asparate aminotransferase (AST), albumin, uric acid, creatinine and
high-sensitivity CRP (hs-CRP) – were assessed according to categories of parental history of T2D.
Results In age and sex–adjusted analyses, offspring with parental history of T2D had significantly higher ALT
[b = 0Æ074; 95% confidence interval (95%CI), 0Æ023–0Æ126] and AST levels (b = 0Æ033; 95%CI, 0Æ001 to 0Æ066)
and a trend towards higher HbA1c (b = 0Æ011; 95%CI, )0Æ001 to 0Æ024) and GGT (b = 0Æ049; 95%CI, )0Æ015 to
0Æ112) levels. Adjustment for diet, smoking, alcohol intake, physical activity and educational level modestly atten-
uated the magnitude of these associations, but they remained significant for ALT and borderline significant for
AST. After further adjustment for adiposity, additional attenuation was observed, but the association remained
significant for ALT. Only maternal history of T2D was associated with higher ALT levels. T2D in both parents
was associated with increased levels of all liver enzymes, but the association remained significant for GGT after
adjustment for adiposity. Overall, the modifiable factors explained 21Æ2–45Æ4% of these associations. The
contribution of adiposity was 18Æ2–38Æ9%.
Conclusion We conclude that parental history of T2D was associated with higher non-fasting levels of liver
enzymes in a general population without T2D. Adiposity substantially contributed to these associations. The
contribution of diet and lifestyle factors was modest.
Keywords Adiposity, biomarker, cardiometabolic, diet, lifestyle, parental history, type 2 diabetes.
Eur J Clin Invest 2012; 42 (9): 974–982
Introduction
Type 2 diabetes (T2D) is associated with a broad range of meta-
bolic components. There is evidence suggesting familial trans-
mission of the metabolic components to offspring [1]. Family
history of T2D contains both genetic and environmental infor-
mation [2]. We and others recently demonstrated that diet, life-
style factors and adiposity contribute to T2D risk exerted by
parental history of T2D [3,4]. Diet and lifestyle intervention has
been shown to modify cardiometabolic risk factors [5].
A limited number of studies evaluated the associations of
parental history of T2D with levels of some diabetes-related
metabolic biomarkers [6–10]. These studies found no associ-
ations of parental history of T2D with the inflammatory
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marker high-sensitivity C-reactive protein (hs-CRP), glyca-
emia index HbA1c and blood lipid profile components,
including total, and HDL-cholesterol and triglycerides
[6,7,10]. They, however, found a positive association of
parental history of T2D with the liver enzymes such as
gamma-glutamyltranspeptidase (GGT) in non-diabetic
offspring [6]. Evidence suggests that elevated liver enzymes
as surrogate marker of non-alcoholic fatty liver disease
(NAFLD) comprises a new component of the metabolic
syndrome [11,12]. NAFLD may be linked to uric acid [13],
while uric acid in turn is linked to both the metabolic
syndrome and renal dysfunction [14]. Of note, the associa-
tions of parental history of T2D with uric acid and renal
profile components like serum creatinine have not been
examined yet. Moreover, it is still unclear whether modifi-
able factors including diet, lifestyle and adiposity have any
effects on the associations of parental history of T2D with
aforementioned cardiometabolic biomarkers.
We investigated whether parental history of T2D is asso-
ciated with a broad panel of cardiometabolic biomarkers.
We did this in a random sample of adults without T2D
from the European Prospective Investigation into Cancer
and Nutrition (EPIC) study in the Netherlands (EPIC-NL).
We hypothesize that modifiable factors affect these associa-
tions; we therefore examined to what extent adiposity, diet
and lifestyle factors contribute to the associations of paren-
tal history of T2D with levels of biomarkers.
Methods
Study population and design
This study was performed in a random sample (6Æ5%,
n = 2604) of the baseline cohort of the EPIC-NL study in the
Netherlands (n = 40 011). The EPIC-NL cohort comprises the
Monitoring Project on Risk Factors for Chronic Diseases
(MORGEN), and Prospect cohorts set up simultaneously
between 1993 and 1997. Details of the study design, recruit-
ment and study procedures (including the random sample)
were described in detail elsewhere [15].
From the random sample, we excluded 43 participants
who had T2D (mainly defined by self-report and verified
by medical records) and 560 with missing data on baseline
characteristics, extreme values for energy intake (< 450 or
> 6000 kcal ⁄day) or unknown parental history of T2D, leav-
ing 2001 participants for this cross-sectional analysis. The
baseline characteristics of excluded participants were similar
to those who were included in our analysis (Table S1). We
asked participants whether their biological mother and ⁄or
father had been diagnosed with T2D. Parental history of
T2D was categorized as none, any parent(s) (mother and ⁄or
father), maternal only, paternal only or both parental.
All participants gave written informed consent prior to study
inclusion. The EPIC-NL cohort complies with the Declaration
of Helsinki and was approved by the relevant local Medical
Ethics Committee. Reporting of the study conforms to STROBE
along with references to STROBE and the broader EQUATOR
guidelines [16].
Biomarker measurements
We collected non-fasting blood samples from participants at
baseline. Blood samples were fractionated into aliquots and
stored at )196 C for future use. HbA1c was measured in
erythrocytes using an immunoturbidimetric latex test.
Biomarkers were assessed in EDTA (in MORGEN cohort) or
citrate (in Prospect cohort) plasma. We compared EDTA and
citrate measurements and validated these against serum in a
sample of 50 participants, observing very good to excellent cor-
relations [15]. Albumin and creatinine (Jaffe´ method) were mea-
sured using a colorimetric method. Alanine aminotransferase
(ALT), asparate aminotransferase (AST), GGT, total cholesterol,
triglycerides and uric acid were measured using enzymatic
methods, whereas hs-CRP was measured with a turbidimetric
method. We measured HDL and LDL-cholesterol using a
homogeneous assay with enzymatic endpoint. These assays
were all performed on an autoanalyser (LX20; Beckman
Coulter, Mijdrecht, the Netherlands). Our technicians were
blinded to the participants’ characteristics.
Statistical analysis
We used generalized linear models to assess the association
between parental history of T2D and cardiometabolic biomar-
kers in model 1, adjusted for cohort, age and sex. Model 2
was further adjusted for smoking, alcohol use, physical activ-
ity level, educational level, total energy intake, and energy-
adjusted intakes of fat, protein, carbohydrate, fibre, vitamin C
and vitamin E [3,15], while model 3 also included body mass
index (BMI) and waist circumference. The b regression coeffi-
cients (95%CI) for biomarker levels (indicating the increase or
decrease in log-transformed level of biomarker) in each cate-
gory of parental history of T2D were calculated. Inclusion of
these factors in the model would be expected to attenuate the
b coefficients [3]. We calculated the percentage attenuation of
the b coefficients for each category of parental history of T2D.
Percentage attenuation of b coefficient was calculated as: (b
coefficient before addition ) b coefficient after addition) ⁄ (b
coefficient before addition) · 100. To account for the use of
non-fasting blood samples, we performed sensitivity analyses
after exclusion of those with high blood glucose (‡ 7Æ8 mM;
n = 34) and we adjusted the associations for time since last
meal or drink (postprandial time). We considered a P-value of
0Æ05 or less from two-sided tests statistically significant. All
the statistical analyses were carried out using Statistical
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Package for Social Sciences version 17 (SPSS Inc, Chicago, IL,
USA).
Results
We summarized baseline characteristics of the study popula-
tion according to parental history of T2D in Table 1. When com-
pared with offspring without parental history of T2D, those
who reported any parental history of T2D had higher levels of
HbA1c, LDL-cholesterol, ALT and GGT. Moreover, a trend
towards higher AST levels in offspring with parental history of
T2D than those without parental history of T2D was found.
We observed no difference for levels of other biomarkers
between each category of parental history of T2D. In our data
set, there were 560 individuals with missing data on baseline
characteristics. We presented the comparison between included
and excluded participants and found no differences (Table S1).
In regression model adjusted for cohort, age and sex, BMI
was associated with levels of liver enzymes (b ranged from
0Æ096 to 0Æ316; P < 0Æ001) in both offspring with and without
parental history of T2D. The R2 change after adding BMI to this
model showed to what extent BMI could explain the variation
of levels of liver enzymes. This contribution of BMI in the varia-
tion of AST (6Æ9% vs. 0Æ9%) and GGT (9Æ9% vs. 3Æ8%) was stron-
ger for those with parental history of T2D.
Parental history of diabetes and cardiometabolic
biomarkers
The association between parental history of T2D and biomarker
levels in offspring adjusted for covariates is shown in Table 2.
In model 1, offspring with any parental history of T2D had
significantly higher levels of ALT (b = 0Æ074; 95%CI, 0Æ023–
0Æ126) and AST (b = 0Æ033; 95%CI, 0Æ001–0Æ066). Moreover, lev-
els of HbA1c (b = 0Æ011; 95%CI, )0Æ001 to 0Æ024) and GGT
(b = 0Æ049; 95%CI, )0Æ015 to 0Æ112) tended to be higher in
offspring with any parental history of T2D. The association
between any parental history of T2D and level of these biomar-
ker levels was modestly attenuated in model 2. Adjustment for
adiposity (model 3) further attenuated the associations, but
they remained significant for ALT (b = 0Æ052; 95%CI, 0Æ002–
0Æ101) and borderline significant for AST (b = 0Æ026; 95%CI,
)0Æ006 to 0Æ059). The overall attenuations for HbA1c, ALT and
AST were 36Æ4%, 29Æ7% and 21Æ2%, respectively.
To examine to what extent adiposity itself contribute to the
association of parental history of T2D with HbA1c and liver
enzymes, we separately added parameters of obesity and obes-
ity (BMI ‡ 30 kg ⁄m2) to model 1. Parameters of obesity
explained 18Æ2%, 28Æ4% and 21Æ2%, respectively, of the associa-
tion of parental history of T2D with HbA1c ALT and AST,
while presence of obesity explained 9Æ1%, 10Æ8% and 9Æ1%,
respectively, of these associations.
Maternal vs. paternal history of diabetes
In subsequent analyses, we examined whether biomarker levels
differed by maternal or paternal history of T2D. In model 1,
offspring with only maternal history of T2D had higher ALT
levels (b = 0Æ084; 95%CI, 0Æ020–0Æ149). Offspring with only
paternal history of T2D had higher albumin levels (b = 0Æ017;
95%CI, 0Æ002–0Æ032). Those with both maternal and paternal
history of T2D had higher GGT levels (b = 0Æ423; 95%CI, 0Æ178–
0Æ668), higher ALT levels (b = 0Æ262; 95%CI, 0Æ062–0Æ462) and
higher AST levels (b = 0Æ129; 95%CI, (0Æ000–0Æ257). In model 3,
statistically significant higher levels of GGT (b = 0Æ331; 95%CI,
0Æ095–0Æ566) were found for offspring with both diabetic par-
ents, and higher levels of ALT (b = 0Æ065; 95%CI, 0Æ003–0Æ127)
for offspring with only maternal history of T2D (Table 2). The
overall attenuation of the association of maternal history of T2D
with ALT was 22Æ6%. The overall attenuations of the association
of both parental history of T2D with AST, ALT and GGT were
34Æ8%, 45Æ4% and 21Æ7%, respectively.
To examine to what extent adiposity itself contribute to the
associations of maternal and both parental history of T2D with
most-related biomarkers, we separately added parameters of
adiposity and obesity to model 1 in each category. Parameters
of obesity explained 23Æ8% of the association of maternal history
of T2D with ALT, but presence of obesity explained 4Æ8% of this
association. Parameters of obesity explained 38Æ9% and 26Æ7%,
respectively, of the association of both parental history of T2D
with ALT and GGT. Obesity explained 26Æ3% and 18Æ4%,
respectively, of these associations.
In sensitivity analyses, we excluded those with high blood
glucose (‡ 7Æ8 mM; n = 34) and further adjusted for time since
last meal or drink (postprandial time) and observed similar
results (data not shown).
Discussion
In this cross-sectional analysis, we found that any parental his-
tory of T2D was associated with higher levels of liver enzymes
(ALT and AST) in adults without T2D. This was particularly
true for maternal history of T2D. Offspring with both diabetic
parents had higher GGT levels as well, whereas those who
reported only paternal diabetes had higher albumin levels. The
associations between parental history of diabetes and liver
enzymes were partly explained by diet and lifestyle factors
(smoking status, alcohol consumption, physical activity and
educational level). The parameters of adiposity contributed
substantially to these associations.
Given the extensive information about modifiable factors of
the participants, we were able to show the contribution of these
factors in the associations between parental history of diabetes
T2D and a panel of biomarkers in adults without T2D.
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Table 1 Baseline characteristics of the random sample according to parental history of type 2 diabetes (n = 2001)
Variables














(n = 21) P-value* P-value†
Age, year 49Æ5 (12Æ2) 52Æ0 (9Æ3) 52Æ3 (9Æ8) 52Æ2 (8Æ8) 47Æ6 (9Æ4) <0Æ001 0Æ001
Female 1220 (75Æ7) 300 (76Æ9) 107 (75Æ7) 175 (77Æ1) 18 (85Æ7) 0Æ62 0Æ72
Body mass index, kg ⁄ m2 25Æ7 (4Æ0) 26Æ7 (3Æ9) 26Æ4 (3Æ8) 26Æ6 (3Æ8) 29Æ1 (5Æ0) <0Æ001 <0Æ001
Waist circumference, cm 85Æ3 (11Æ4) 87Æ2 (11Æ1) 86Æ6 (10Æ9) 87Æ2 (10Æ9) 90Æ9 (14Æ0) 0Æ003 0Æ01
Alcohol consumption,
g ⁄ week
11Æ5 (15Æ0) 9Æ7 (12Æ8) 10Æ4 (13Æ6) 9Æ3 (11Æ9) 9Æ3 (1Æ7) 0Æ02 0Æ13
Current smoker 489 (30Æ4) 107 (27Æ4) 36 (25Æ4) 66 (29Æ1) 5 (23Æ8) 0Æ26 0Æ57
Low educational level‡ 916 (56Æ9) 244 (62Æ6) 77 (54Æ2) 156 (68Æ7) 11 (52Æ4) 0Æ04 0Æ005
Physically active§ 520 (32Æ3) 141 (36Æ2) 46 (32Æ4) 84 (37Æ0) 11 (52Æ4) 0Æ14 0Æ35
Total energy intake,
kcal ⁄ day
2048Æ2 (599Æ1) 1980Æ2 (582Æ5) 1921Æ6 (551Æ6) 2023Æ3 (601Æ4) 1909Æ3 (563Æ2) 0Æ04 0Æ07
Nutrient intake¶, g ⁄ day
Protein 75Æ8 (10Æ9) 77Æ7 (10Æ9) 78Æ1 (9Æ7) 77Æ0 (11Æ4) 82Æ1 (11Æ7) 0Æ003 0Æ004
Fat 77Æ3 (11Æ2) 78Æ4 (10Æ5) 77Æ1 (9Æ8) 79Æ1 (10Æ7) 78Æ5 (12Æ2) 0Æ11 0Æ16
Carbohydrates 221Æ4 (31Æ2) 220Æ3 (23Æ4) 220Æ8 (27Æ9) 220Æ3 (28Æ1) 216Æ7 (34Æ2) 0Æ55 0Æ87
Fibre 23Æ3 (4Æ6) 24Æ0 (4Æ7) 24Æ1 (4Æ6) 23Æ9 (4Æ8) 24Æ6 (3Æ8) 0Æ008 0Æ06
Vitamin C, mg ⁄ day 110Æ6 (46Æ2) 114Æ4 (44Æ1) 112Æ1 (39Æ4) 115Æ2 (46Æ6) 121Æ9 (47Æ9) 0Æ14 0Æ38
Vitamin E, mg ⁄ day 12Æ1 (3Æ2) 12Æ3 (3Æ3) 11Æ9 (2Æ8) 12Æ5 (3Æ6) 12Æ0 (3Æ0) 0Æ33 0Æ23
HbA1c, % 5Æ36 (5Æ02–5Æ71) 5Æ46 (5Æ14–5Æ82) 5Æ52 (5Æ18–5Æ85) 5Æ44 (5Æ12–5Æ80) 5Æ45 (4Æ91–5Æ69) <0Æ001 0Æ003
Total cholesterol, mM 5Æ2 (4Æ6–5Æ9) 5Æ3 (4Æ6–6Æ0) 5Æ3 (4Æ7–6Æ0) 5Æ3 (4Æ6–6Æ0) 5Æ1 (4Æ8–6Æ4) 0Æ16 0Æ56
HDL-C, mM 1Æ21 (1Æ02–1Æ47) 1Æ21 (1Æ02–1Æ45) 1Æ22 (1Æ04–1Æ46) 1Æ22 (1Æ00–1Æ45) 1Æ16 (1Æ02–1Æ46) 0Æ92 0Æ97
LDL-C, mM 3Æ07 (2Æ46–3Æ68) 3Æ16 (2Æ61–3Æ75) 3Æ25 (2Æ71–3Æ70) 3Æ16 (2Æ59–3Æ81) 3Æ00 (2Æ59–3Æ77) 0Æ02 0Æ11
Triglycerides, mM 1Æ34 (0Æ92–1Æ95) 1Æ28 (0Æ96–1Æ97) 1Æ39 (0Æ96–1Æ97) 1Æ23 (0Æ96–2Æ02) 1Æ48 (0Æ80–1Æ48) 0Æ79 0Æ85
ALT, IU ⁄ L 14Æ5 (11Æ9–18Æ3) 14Æ9 (12Æ2–20Æ4) 14Æ5 (11Æ97–19Æ52) 15Æ1 (12Æ4–20Æ8) 15Æ4 (12Æ4–27Æ5) 0Æ008 0Æ03
AST, IU ⁄ L 19Æ9 (17Æ4–23Æ5) 20Æ2 (17Æ4–24Æ5) 20Æ4 (17Æ5–24Æ2) 20Æ1 (17Æ3–24Æ6) 21Æ7 (17Æ8–28Æ4) 0Æ28 0Æ54
GGT, IU ⁄ L 20Æ3 (16Æ5–27Æ7) 21Æ3 (17Æ1–29Æ5) 20Æ3 (16Æ2–27Æ5) 21Æ8 (17Æ7–29Æ4) 32Æ2 (19Æ2–43Æ3) 0Æ03 0Æ007
Albumin, g ⁄ L 38Æ7 (34Æ3–42Æ8) 37Æ5 (34Æ3–42Æ1) 38Æ1 (34Æ5–41Æ9) 37Æ1 (34Æ0–42Æ0) 39Æ6 (35Æ1–44Æ4) 0Æ18 0Æ22
Uric acid, lM 247Æ6 (210Æ2–298Æ6) 251Æ5 (209Æ3–293Æ4) 252Æ8 (215Æ5–288Æ1) 248Æ9 (208Æ1–299Æ5) 241Æ1 (196Æ7–349Æ5) 0Æ92 1Æ00
Creatinine, lM 61Æ4 (53Æ4–71Æ6) 60Æ8 (54Æ1–70Æ6) 61Æ3 (55Æ2–70Æ9) 60Æ0 (53Æ2–70Æ6) 60Æ9 (55Æ0–67Æ0) 0Æ33 0Æ70
hs-CRP, mg ⁄ L 1Æ24 (0Æ56–2Æ69) 1Æ26 (0Æ66–2Æ70) 1Æ27 (0Æ71–2Æ53) 1Æ24 (0Æ61–2Æ90) 1Æ15 (0Æ69–2Æ49) 0Æ42 0Æ88
HbA1c, glycosylated haemoglobin; HDL-C, high-density cholesterol; LDL-C, low-density cholesterol; ALT, alanine transaminase; AST, aspartate transaminase; GGT, gamma glutamyl trans-
peptidase; hs-CRP, high-sensitivity C-reactive protein.
Data were given as mean (SD) or median (IQR) for continuous variables and numbers (percentage) for categorical variables.
*For the comparison between participants with any parental history of type 2 diabetes and none using chi-squared test (categorical data), and t-test or Mann–Whitney U-test (continuous
data).
†For the comparison between participants with paternal, maternal or both history of type 2 diabetes and none (as referent) using chi-squared test (categorical data), and ANOVA or Kruskal–
Wallis (continuous data).
‡Low education level was assigned for participants who had primary education up to completing intermediate vocational education.
§Physical activity level was defined based on Cambridge Physical Activity Index.
¶Intakes of nutrients were adjusted for total energy intake and given as g ⁄ day unless otherwise indicated.
European Journal of Clinical Investigation Vol 42 977
PARENTAL DIABETES AND CARDIOMETABOLIC BIOMARKERS
Table 2 Association between parental history of type 2 diabetes and offspring biomarker levels (n = 2001)
Log-transformed biomarker
b regression coefficients (95%CI) by category of parental history of type 2 diabetes*
Any parents (n = 390) Only father (n = 142) Only mother (n = 227) Both parents (n = 21)
HbA1c, %
Model 1 0Æ011 ()0Æ001 to 0Æ024) 0Æ015 ()0Æ004 to 0Æ035) 0Æ008 ()0Æ008 to 0Æ024) 0Æ019 ()0Æ030 to 0Æ067)
P-value 0Æ08 0Æ12 0Æ32 0Æ45
Model 2 0Æ009 ()0Æ003 to 0Æ022) 0Æ016 ()0Æ004 to 0Æ035) 0Æ004 ()0Æ011 to 0Æ020) 0Æ019 ()0Æ029 to 0Æ068)
P-value 0Æ15 0Æ11 0Æ59 0Æ43
Model 3 0Æ007 ()0Æ005 to 0Æ020) 0Æ015 ()0Æ005 to 0Æ034) 0Æ003 ()0Æ012 to 0Æ019) 0Æ009 ()0Æ039 to 0Æ057)
P-value 0Æ24 0Æ14 0Æ73 0Æ71
Total cholesterol, mM
Model 1 0Æ015 ()0Æ011 to 0Æ041) 0Æ014 ()0Æ026 to 0Æ053) 0Æ018 ()0Æ014 to 0Æ051) )0Æ010 ()0Æ110 to 0Æ090)
P-value 0Æ25 0Æ50 0Æ26 0Æ84
Model 2 0Æ015 ()0Æ011 to 0Æ040) 0Æ014 ()0Æ026 to 0Æ054) 0Æ018 ()0Æ015 to 0Æ050) )0Æ012 ()0Æ112 to 0Æ088)
P-value 0Æ26 0Æ48 0Æ29 0Æ81
Model 3 0Æ013 ()0Æ012 to 0Æ039) 0Æ014 ()0Æ026 to 0Æ054) 0Æ016 ()0Æ016 to 0Æ048) )0Æ020 ()0Æ120 to 0Æ080)
P-value 0Æ31 0Æ49 0Æ33 0Æ70
HDL-C, mM
Model 1 0Æ020 ()0Æ016 to 0Æ056) 0Æ027 ()0Æ029 to 0Æ083) 0Æ022 ()0Æ023 to 0Æ067) )0Æ051 ()0Æ191 to 0Æ089)
P-value 0Æ27 0Æ34 0Æ33 0Æ47
Model 2 0Æ027 ()0Æ007 to 0Æ061) 0Æ025 ()0Æ028 to 0Æ078) 0Æ036 ()0Æ007 to 0Æ079) )0Æ063 ()0Æ196 to 0Æ070)
P-value 0Æ12 0Æ36 0Æ10 0Æ35
Model 3 0Æ028 ()0Æ005 to 0Æ062) 0Æ031 ()0Æ020 to 0Æ081) 0Æ037 ()0Æ006 to 0Æ080) 0Æ002 ()0Æ125 to 0Æ128)
P-value 0Æ10 0Æ23 0Æ10 0Æ97
LDL-C, mM
Model 1 0Æ034 ()0Æ008 to 0Æ075) 0Æ036 ()0Æ028 to 0Æ101) 0Æ036 ()0Æ016 to 0Æ089) )0Æ012 ()0Æ175 to 0Æ150)
P-value 0Æ12 0Æ27 0Æ18 0Æ88
Model 2 0Æ030 ()0Æ012 to 0Æ072) 0Æ035 ()0Æ030 to 0Æ100) 0Æ032 ()0Æ021 to 0Æ084) )0Æ018 ()0Æ180 to 0Æ144)
P-value 0Æ15 0Æ29 0Æ24 0Æ83
Model 3 0Æ025 ()0Æ016 to 0Æ067) 0Æ033 ()0Æ031 to 0Æ097) 0Æ027 ()0Æ025 to 0Æ079) )0Æ045 ()0Æ207 to 0Æ117)
P-value 0Æ23 0Æ31 0Æ31 0Æ59
Triglycerides, mM
Model 1 )0Æ0002 ()0Æ074 to 0Æ075) 0Æ032 ()0Æ083 to 0Æ147) )0Æ017 ()0Æ111 to 0Æ076) )0Æ026 ()0Æ315 to 0Æ263)
P-value 1Æ00 0Æ58 0Æ72 0Æ86
Model 2 )0Æ0001 ()0Æ074 to 0Æ074) 0Æ046 ()0Æ069 to 0Æ160) )0Æ029 ()0Æ122 to 0Æ064) 0Æ003 ()0Æ283 to 0Æ289)
P-value 1Æ00 0Æ43 0Æ56 0Æ98
Model 3 )0Æ022 ()0Æ092 to 0Æ049) 0Æ037 ()0Æ072 to 0Æ146) )0Æ050 ()0Æ139 to 0Æ038) )0Æ115 ()0Æ389 to 0Æ159)
P-value 0Æ54 0Æ51 0Æ26 0Æ41
ALT, IU ⁄ L
Model 1 0Æ074 (0Æ023 to 0Æ126) 0Æ030 ()0Æ050 to 0Æ110) 0Æ084 (0Æ020 to 0Æ149) 0Æ262 (0Æ062 to 0Æ462)
P-value 0Æ005 0Æ46 0Æ01 0Æ01
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Table 2 Continued
Log-transformed biomarker
b regression coefficients (95%CI) by category of parental history of type 2 diabetes*
Any parents (n = 390) Only father (n = 142) Only mother (n = 227) Both parents (n = 21)
Model 2 0Æ068 (0Æ017 to 0Æ120) 0Æ026 ()0Æ054 to 0Æ106) 0Æ080 (0Æ016 to 0Æ145) 0Æ232 (0Æ032 to 0Æ431)
P-value 0Æ01 0Æ52 0Æ01 0Æ02
Model 3 0Æ052 (0Æ002 to 0Æ101) 0Æ017 ()0Æ059 to 0Æ094) 0Æ065 (0Æ003 to 0Æ127) 0Æ143 ()0Æ049 to 0Æ335)
P-value 0Æ04 0Æ66 0Æ04 0Æ14
AST, IU ⁄ L
Model 1 0Æ033 (0Æ001 to 0Æ066) 0Æ028 ()0Æ023 to 0Æ080) 0Æ027 ()0Æ015 to 0Æ068) 0Æ129 (0Æ000 to 0Æ257)
P-value 0Æ05 0Æ28 0Æ21 0Æ05
Model 2 0Æ032 ()0Æ001 to 0Æ065) 0Æ026 ()0Æ025 to 0Æ077) 0Æ028 ()0Æ014 to 0Æ069) 0Æ112 ()0Æ016 to 0Æ240)
P-value 0Æ06 0Æ30 0Æ19 0Æ08
Model 3 0Æ026 ()0Æ006 to 0Æ059) 0Æ024 ()0Æ026 to 0Æ075) 0Æ022 ()0Æ019 to 0Æ063) 0Æ084 ()0Æ042 to 0Æ211)
P-value 0Æ11 0Æ34 0Æ28 0Æ19
GGT, IU ⁄ L
Model 1 0Æ049 ()0Æ015 to 0Æ112) )0Æ027 ()0Æ125 to 0Æ071) 0Æ061 ()0Æ019 to 0Æ140) 0Æ423 (0Æ178 to 0Æ668)
P-value 0Æ13 0Æ59 0Æ13 0Æ001
Model 2 0Æ058 ()0Æ005 to 0Æ121) )0Æ015 ()0Æ111 to 0Æ082) 0Æ069 ()0Æ009 to 0Æ148) 0Æ433 (0Æ191 to 0Æ675)
P-value 0Æ07 0Æ76 0Æ08 <0Æ001
Model 3 0Æ039 ()0Æ022 to 0Æ100) )0Æ026 ()0Æ119 to 0Æ068) 0Æ053 ()0Æ023 to 0Æ129) 0Æ331 (0Æ095 to 0Æ566)
P-value 0Æ21 0Æ59 0Æ17 0Æ006
Albumin, g ⁄ L
Model 1 0Æ006 ()0Æ003 to 0Æ016) 0Æ017 (0Æ002 to 0Æ032) )0Æ002 ()0Æ014 to 0Æ011) 0Æ021 ()0Æ017 to 0Æ059)
P-value 0Æ20 0Æ03 0Æ80 0Æ27
Model 2 0Æ006 ()0Æ004 to 0Æ016) 0Æ015 (0Æ000 to 0Æ030) )0Æ001 ()0Æ013 to 0Æ011) 0Æ015 ()0Æ023 to 0Æ052)
P-value 0Æ23 0Æ04 0Æ90 0Æ44
Model 3 0Æ006 ()0Æ003 to 0Æ016) 0Æ016 (0Æ001 to 0Æ031) )0Æ0005 ()0Æ013 to 0Æ012) 0Æ018 ()0Æ020 to 0Æ055)
P-value 0Æ19 0Æ04 0Æ94 0Æ35
Uric acid, lM
Model 1 0Æ006 ()0Æ024 to 0Æ036) )0Æ002 ()0Æ050 to 0Æ044) 0Æ006 ()0Æ032 to 0Æ044) 0Æ060 ()0Æ058 to 0Æ177)
P-value 0Æ69 0Æ92 0Æ74 0Æ32
Model 2 0Æ006 ()0Æ024 to 0Æ037) )0Æ0004 ()0Æ047 to 0Æ047) 0Æ005 ()0Æ032 to 0Æ044) 0Æ052 ()0Æ066 to 0Æ169)
P-value 0Æ71 0Æ99 0Æ75 0Æ39
Model 3 0Æ006 ()0Æ035 to 0Æ023) )0Æ009 ()0Æ053 to 0Æ036) )0Æ004 (0Æ040 to 0Æ032) )0Æ016 ()0Æ128 to 0Æ096)
P-value 0Æ68 0Æ71 0Æ84 0Æ77
Creatinine, mg ⁄ L
Model 1 )0Æ013 ()0Æ039 to 0Æ012) )0Æ007 ()0Æ046 to 0Æ033) )0Æ020 ()0Æ052 to 0Æ012) 0Æ013 ()0Æ086 to 0Æ112)
P-value 0Æ30 0Æ74 0Æ22 0Æ79
Model 2 )0Æ011 ()0Æ036 to 0Æ015) )0Æ006 ()0Æ046 to 0Æ033) )0Æ016(0Æ048 to 0Æ016) 0Æ014 ()0Æ084 to 0Æ113)
P-value 0Æ40 0Æ76 0Æ32 0Æ77
Model 3 )0Æ013 ()0Æ038 to 0Æ013) )0Æ007 ()0Æ047 to 0Æ037) )0Æ017 (0Æ049 to 0Æ015) 0Æ006 ()0Æ093 to 0Æ105)
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Nevertheless, our study has some limitations. The study is a
cross-sectional investigation, and causal relationships cannot be
inferred. Another limitation is that parental history of T2D was
obtained by self-report. Furthermore, we excluded the individ-
uals with missing data or unknown parental history of T2D.
However, most of the baseline characteristics of excluded par-
ticipants were similar to those who were included in our analy-
sis. Therefore, it is unlikely that this may have led to selection
bias in some categories of parental history of T2D. We used
data on non-fasting blood samples as fasting samples were not
available, but further adjustment for postprandial time did not
change the results. Although non-fasting conditions could be
argued as a severe limitation of our study, there is evidence
suggesting that overnight fasting status might have minimal
effects on concentrations of most biomarkers which we studied
[17,18], also in our cohort [19]. Of note, data on non-fasting
lipids such as triglycerides and inflammation-related biomar-
kers such as CRP and adiponectin have been shown to improve
the risk prediction of T2D and cardiovascular events indepen-
dent of traditional cardiometabolic risk profile [18–20]. Finally,
we had no data on more specific factors to T2D, such as
HOMA ⁄ insulin and adiponectin to examine their associations
with parental history of T2D, but the metabolic syndrome was
not a primary focus of this study.
Among different cardiometabolic biomarkers, only liver
enzymes were associated with parental history of T2D. Our
findings are in line with the limited prior information, suggest-
ing that female workers with family history of T2D had ele-
vated levels of ALT, AST and GGT [6]. However, this study
also observed an association with triglycerides, which we could
not confirm [6]. Similar to our results, the recent studies also
showed no association of family history of T2D with lipid
profile components and proinflammatory markers in adults
without T2D [7,8,10]. Our results were similar by excluding
those with high non-fasting glucose concentrations and were
therefore more likely to be a direct consequence of parental
history of T2D rather than secondary to pre-diabetes state.
Adjusting for diet and lifestyle attenuated the association
between parental history of T2D and liver function profile. This
supports the suggestion of lifestyle modification has positive
effect on cardiometabolic risk [5]. Further adjustment for
adiposity led to a more attenuation in the associations. In fact,
this indicated that adiposity contributed to parental transmis-
sion of liver function profile independent from diet and lifestyle
factors. Furthermore, increased adiposity, in itself, could sub-
stantially explain the associations of parental history of T2D
with HbA1c and liver enzymes. These findings are generally in
line with those of other epidemiologic studies, showing that
adiposity plays an important role in transmission of cardiomet-
abolic risk [10,21]. Mild elevated levels of liver enzymes may
have occurred in early or subclinical metabolic abnormality
underlying NAFLD. Of note, the lack of association of parental
history of T2D with markers of glycaemia, lipids and low-grade
inflammation may show that these subclinical changes in liver
function are important for further progression to pre-diabetes
state and T2D [22,23]. This extends the available information
for a possible link between NAFLD, adiposity and T2D. Of
note, these traits partly share common genetic and environmen-
tal components [24]. Further prospective investigations are
warranted, showing whether the link between liver function
and adiposity contributes to transmission of risk of T2D and its
complications to the next generation [2–4].
In our study, there was a stronger association of maternal his-
tory of T2D with liver enzymes. This difference might be partly
explained by genetic and environmental conditions such as
X-linked traits, gene imprinting intra-uterine programming and
Table 2 Continued
Log-transformed biomarker
b regression coefficients (95%CI) by category of parental history of type 2 diabetes*
Any parents (n = 390) Only father (n = 142) Only mother (n = 227) Both parents (n = 21)
P-value 0Æ34 0Æ72 0Æ28 0Æ91
hs-CRP, mg ⁄ L
Model 1 0Æ028 ()0Æ127 to 0Æ182) )0Æ011 ()0Æ250 to 0Æ229) 0Æ050()0Æ144 to 0Æ244) 0Æ046 ()0Æ554 to 0Æ647)
P-value 0Æ73 0Æ93 0Æ61 0Æ88
Model 2 0Æ035 ()0Æ118 to 0Æ188) 0Æ019 ()0Æ211 to 0Æ264) 0Æ039 ()0Æ154 to 0Æ231) 0Æ103 ()0Æ491 to 0Æ696)
P-value 0Æ65 0Æ83 0Æ69 0Æ73
Model 3 )0Æ018 ()0Æ165 to 0Æ130) )0Æ015 ()0Æ243 to 0Æ214) )0Æ004 ()0Æ190 to 0Æ181) )0Æ187 ()0Æ761 to 0Æ386)
P-value 0Æ81 0Æ90 0Æ96 0Æ52
HbA1c, glycosylated haemoglobin; HDL-C, high-density cholesterol; LDL-C, low-density cholesterol; ALT, alanine transaminase; AST, aspartate transaminase; GGT, gamma glutamyl
transpeptidase; hs-CRP, high-sensitivity C-reactive protein.
*Model 1 was adjusted for cohort, age and sex. Model 2 was adjusted for model 1 plus smoking, alcohol use, physical activity level, educational level, total energy intake and energy-
adjusted dietary factors, including the amount of intake of fat, protein, carbohydrate, fibre, vitamin C and vitamin E. Model 3 was adjusted for model 2 plus body mass index and waist
circumference. Significant P values were indicated in bold type.
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a more prominent maternal role in raising children. A recent
study among Japanese men showed that maternal but not
paternal adiposity was associated with a higher level of ALT
[25]. Similar to our data, another study on offspring of diabetic
parents has shown that defects in insulin sensitivity and b-cell
glucose sensitivity were accentuated along the maternal line of
inheritance [10]. The specific relation of maternal history of T2D
and liver enzymes observed in our study could also be
explained by the fact that the mother might have a more promi-
nent role in raising her children from early life, that is, during
pregnancy, to later life. For example, it has been shown that
maternal pre-pregnancy overweight increased the risk of
offspring overweight and abdominal obesity [26]. Adiposity
in turn associates with elevated liver enzymes and NAFLD
[27–29].
In conclusion, we found that parental history of T2D was
associated with higher non-fasting levels of ALT, AST and GGT
in a general population without T2D. Adiposity, substantially,
contributed to the associations between parental history of T2D
and liver function profile. The contribution of diet and lifestyle
factors was modest.
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